Potential Mechanisms of Neurologic Disease in HIV Infection

Melvyn P. Heyes
Section on Analytical Biochemistry
Laboratory of Clinical Science
National Institute of Mental Health
Bethesda, Maryland 20892.


1. Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors and quinolinic acid in AIDS brains. J Clin Invest 1993;91:2769–2775.

2. Arendt G, Hefter H, Elsing C, Strohmeyer G, Freund HJ. Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit. J Neurol 1990;237:362–368.

3. Barks JD, Nair MPN, Schwartz SA, Silverstein FS Potentiation of N-methyl-D-aspartate-mediated brain injury by a human immunodeficiency virus-1-derived peptide in perinatal rodents. Pediatr Res 1993;34:192–198.

4. Bernton EW, Bryant HU, Decoster MA, Orenstein JM, Ribas JL, Meltzer MS, Gendelman HE. No direct neuronotoxicity by HIV-1 virions or culture fluids from HIV-1-infected T cells or monocytes. AIDS Res Hum Retroviruses 1992;8:495–503.

5. Blight AR, Saito K, Heyes MP. Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury. Brain Res 1993;632:314–316.

6. Brenneman DE, Buzy JM, Ruff MR, Pert CB. Peptide T sequences prevent neuronal death produced by the envelope protein (gp120) of the human immunodeficiency virus. Drug Dev Res 1988;15:361–369.

7. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988;335:639–642.

8. Brouwers P, Heyes MP, Moss H, Wolters P, El-Amin D, Poplack D, Markey SP, et al. Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type-1 disease: relationships to clinical status and therapeutic response. J Infect Dis 1993;168:1380–1386.

9. Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho E-S, Cornblath DR, et al. Consensus report. HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1991;1:143–152.

10. Buzy J, Brenneman DE, Pert CB, Martin A, Salazar A, Ruff MR. Potent gp120-like neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T. Brain Res 1992;598:10–18.

11. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6. Proc Natl Acad Sci USA 1993;90:10061–10065.

12. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989;45:535–541.

13. Chao CC, Gekker G, Hu S, Peterson PK. Human microglial cell defense against Toxoplasma gondii: the role of cytokines. J Immunol 1994;152:1246–1252.

14. Clerici M, Shearer GM. A TH1{ewc MVIMG, MVIMAGE,!rtarrow.bmp}TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107–111.

15. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992;42:1736–1739.

16. Dawson VL, Dawson TM, Uhl GR, Snyder SH. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 1993;90:3256–3259.

17. DeCarli C, Civitello LA, Brouwers P, Pizzo PA. The prevalence of computed axial tomographic abnormalities of the cerebrum in 100 consecutive children symptomatic with the HIV. Ann Neurol 1993;34:189–205.

18. Desrosiers RC, Hansen-Moosa A, Mori K, Bouvier DP, King NW, Daniel MD, Ringler DJ Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions that are not essential for the development of AIDS. Am J Pathol 1991;139:29–35.

19. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248:364–367.

20. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenic mechanisms. Ann Neurol 1993;33:429–436.

21. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011–1018.

22. Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW, et al. Cytokines and arachidonic acid metabolites produced during human immunodeficiency virus (HIV)-infected macrophage–astrocyte interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 1992;176:1703–1718.

23. Giulian D, Vaca K, Corpuz M. Brain glia release factors with opposing actions upon neuronal survival. J Neurosci 1993;13:29–37.

24. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990;250:1593–1596.

25. Giulian D, Wendt E, Vaca K, Noonan CA. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates the release of neurotoxins from monocytes. Proc Natl Acad Sci USA 1993;90:2769–2773.

26. Glowa JR, Panlilio LV, Brenneman DE, Gozes I, Fridkin M, Hill JM. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res 1992;570:49–53.

27. Greene WC. AIDS and the immune system. Sci Am 1993;269:99–105.

28. Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH, Gonzalez-Scarano F. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 1991;253:320–323.

29. Hayman M, Arbuthnott G, Harkiss G, Brace H, Filippi P, Philippon V, Thomson D, et al. Neurotoxicity of peptide analogues of the transactivating protein tat from maedi-visna virus and human immunodeficiency virus. Neuroscience 1993;53:1–6.

30. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurologic status. Ann Neurol 1991;29:202–209.

31. Heyes MP, Brew BJ, Saito K, Quearry BJ, Price RW, Bhalla RB, Mouradian MM, et al. Inter-relationships between neuroactive kynurenines, neopterin and b2-microglobulin in cerebrospinal fluid and serum of HIV-1 infected patients. J Neuroimmunol 1992;40:71–80.

32. Heyes MP, Jordan EK, Lee K, Saito K, Frank JA, Snoy PJ, Markey SP, et al. Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid and serum quinolinic acid and kynurenic acid. Brain Res 1992;570:237–250.

33. Heyes MP, Kim P, Markey SP. Systemic lipopolysaccharide and pokeweed mitogen increase quinolinic acid content of mouse cerebral cortex. J Neurochem 1988;51:1946–1948.

34. Heyes MP, Rubinow D, Lane C, Markey SP. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann Neurol 1989;26:275–277.

35. Heyes MP, Saito K, Crowley J, Davis LE, Demitrak MA, Der M, Dilling L, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurologic disease. Brain 1992;115:1249–1273.

36. Heyes MP, Saito K, Major EO, Milstein S, Markey SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurologic disease: attenuation of synthesis from L-tryptophan by 6-chloro-tryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993;116:1425–1450.

37. Heyes MP, Saito K, Markey SP. Human macrophages convert L-tryptophan to the neurotoxin quinolinic acid. Biochem J 1992;283: 633–635.

38. Hill JM, Mervis RF, Avidor R, Moody TW, Brenneman DE. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res 1993;603:222–233.

39. Hurtrel B, Chakrabarti L, Hurtrel M, Maire MA, Dormont D, Montagnier L. Early SIV encephalopathy. J Med Primatol 1991;20:159–166.

40. Johnson RT, McArthur JC, Narayan O. The neurobiology of human immunodeficiency virus infections. FASEB J 1988;2:2970–2981.

41. Ketzler S, Weis S, Haug H, Budka H. Loss of neurons in the frontal cortex in AIDS brain. Acta Neuropathol 1990;80:92–94.

42. Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience 1987;25:423–432.

43. Larsson M, Hagberg L, Norkrans G, Forsman A. Indole amine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection. J Neurosci Res 1989;23: 441–446.

44. Lipton SA, Sucher NJ, Kaiser PK. Synergistic effects of HIV coat protein and NMDA-receptor mediated neurotoxicity. Neuron 1991;7:111–118.

45. Mabrouk K, Van RJ, Vives E, Darbon H, Rochat H, Sabatier JM. Lethal neurotoxicity in mice of the basic domains of HIV and SIV Rev proteins. Study of these regions by circular dichroism. FEBS Lett 1991;289:13–17.

46. Martin A, Heyes MP, Salazar AM, Kampen DL, Williams J, Law WA, Coates ME, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J Neuropsychiatr Clin Neurosci 1992;4: 270–279.

47. Martin A, Heyes MP, Salazar AM, Law WA, Williams J. Impaired motor-skill learning, slowed reaction time, and elevated cerebrospinal fluid quinolinic acid in a sub-group of HIV-infected individuals. Neuropsychology 1993;7:149–147.

48. Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest 1992;66:285–291.

49. Merrill JE, Chen ISY. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J 1991;5:2391–2397.

50. Mollace V, Colasanti M, Persichini T, Bagetta G, Lauro GM, Nistico G. HIV gp120 glycoprotein stimulates the inducible iso form of NO synthetase in human cultured astrocytoma cells. Biochem Biophys Res Commun 1993;194:439–445.

51. Navia BA, Cho E-S, Petito CK, Price RW. The AIDS dementia complex. II. Neuropathology. Ann Neurol 1986;19:525–535.

52. Neuen JE, Arendt G, Wendtland B, Jacob B, Schneeweis M, Wechsler W. Frequency and topographical distribution of CD68-positive macrophages and HIV-1 core proteins in HIV-associated brain lesions. Clin Neuropathol 1993;12:315–324.

53. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241–251.

54. Piani D, Frei K, Do KQ, Cuenod M, Fontana A. Murine brain macrophages induce NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett 1991;133:159–162.

55. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988;239:586–592.

56. Pulliam L, Herndier BG, Tang NM, McGrath MS. Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. J Clin Invest 1991;87:503–512.

57. Pulliam L, West D, Haigwood N, Swanson RA. HIV-1 envelope gp120 alters astrocytes in human brain cultures. AIDS Res Hum Retroviruses 1993;9:439–444.

58. Rausch DM, Heyes MP, Murray EA, Lendvay J, Sharer LR, Ward JM, Rehm S, et al. Cytopathologic and neurochemical correlates to motor/cognitive impairments in SIV-infected rhesus monkeys. J Neuropathol Exp Neurol 1994;53:165–175.

59. Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991;16:1139–1143.

60. Sabatier J-M, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, Hue B, et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type-1. J Virol 1991;65:961–967.

61. Saito K, Chen CY, Masana M, Crowley J, Markey SP, Heyes MP. 4-Chloro-3-hydroxyanthranilic acid, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-g stimulated monocytes (THP-1) cells. Biochem. J. 1993;291:11–14.

62. Saito K, Markey SP, Heyes MP. Effects of immune activation on quinolinic acid and kynurenine pathway metabolism in the mouse. Neuroscience 1992;51:25–39.

63. Saito K, Nowak TS Jr, Markey SP, Heyes MP. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J Neurochem 1993;60:180–192.

64. Savio T, Levi G. Neurotoxicity of HIV coat protein gp120, NMDA receptors, and protein kinase C: a study with rat cerebellar granule cell cultures. J Neurosci Res 1993;34:265–272.

65. Spencer DC, Price RW. Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol. 1993;46:655–693.

66. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993;45:309–379.

67. Sweetnam PM, Saab OH, Wroblewski JT, Price CH, Karbon EW and Ferkany JW The envelope glycoprotein of HIV-1 alters NMDA receptor function. Eur J Neurosci 1993;5:275–283.

68. Tardieu M, H:ery C, Peudenier S, Boespflug O and Montagnier L. Human immunodeficiency virus type 1-infected monocytic cells can destroy human neural cells after cell-to-cell adhesion. Ann Neurol 1992;32:11–17.

69. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994;367:188–193.

70. Tyor WR, Glass JD, Griffin JW. Cytokine expression in the brain during AIDS. Ann Neurol 1992;31:249–360.

71. Tyor WR, Power C, Gendelman HE, Markham RB. A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci USA 1993;90:8658–8662.

72. Ushijima H, Ando S, Kunisada T, Schroder HC, Klocking H-P, Kijoa A, Muller WEG. HIV-1 gp120 and NMDA induce protein kinase C translocation differentially in at primary neuronal cultures. J AIDS 1993;6:339–343.

73. Vazeux R, Lacroix CC, Blanche S, Cumont MC, Henin D, Gray F, Boccon GL, et al. Low levels of human immunodeficiency virus replication in the brain tissue of children with severe acquired immunodeficiency syndrome encephalopathy. Am J Pathol 1992; 140:137–144.

74. Weis S, Haug H, Budka H. Astroglial changes in the cerebral cortex of AIDS brains: a morphometric and immunohistochemical investigation. Neuropathol Appl Neurobiol 1993;19:329–335.

75. Weis S, Haug H, Budka H. Neuronal damage in the cerebral cortex of AIDS brains: a morphometric study. Acta Neuropathol (Berl) 1993;85:185–189.

76. Werner ER, Fuchs D, Hausen A. Tryptophan degradation in patients infected by human immunodeficiency syndrome virus. Biol Chem Hoppe Seyler 1988;369:337–340.

77. Werner T, Ferroni S, Saermark T, Brack-Werner R, Banati RB, Mager R, Steinaa L, et al. HIV-1 Nef protein exhibits structural and functional similarity to scorpion peptides interacting with K+ channels. AIDS 1991;5:1301–1308.

78. Wesselingh SL, Power C, Glass JD, Tyor WR, McArthur JC, Faber JM, Griffin JW, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993;33:576–582.

79. Whetsell WO, Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett 1989;97:271–275.

80. Wiley CA, Achim CL, Schrier RD, Heyes MP, McCutchan JA, Grant I. Relationship of cerebrospinal fluid immune activation associated factors to HIV encephalitis. AIDS 1992;6:1299–1307.

81. Wiley CA, Belman AL, Dickson DW, Rubenstein A, Nelson JA. Human immunodeficiency virus within the brains of children with AIDS. Clin Neuropathol 1990;9:1–6.

82. Wiley CA, Mesliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, et al. Neocortical damage during HIV infection. Ann Neurol 1991;29:651–657.

83. Yellon RF, Rose E, Kenna MA, W.J.D, Casselbrant M, Diven WF, Whiteside TL, et al. Sensorineural hearing loss from quinolinic acid: a neurotoxin present in middle ear effusions. Laryngoscope 1994;104:176–181.

Back to Chapter

published 2000